152 related articles for article (PubMed ID: 31314738)
1. Epidemiology of Chemotherapy-Induced Anemia in Patients with Non-Hodgkin Lymphoma.
Cannavale K; Xu H; Xu L; Sattayapiwat O; Rodriguez R; Bohac C; Page J; Chao C
Perm J; 2019; 23():. PubMed ID: 31314738
[TBL] [Abstract][Full Text] [Related]
2. Trends in anemia treatment among patients with five non-myeloid malignancies treated with chemotherapy in a large integrated health care delivery system in California, 2000-2013.
Xu L; Xu H; Cannavale K; Sattayapiwat O; Rodriguez R; Page JH; Chao C
Support Care Cancer; 2016 Jul; 24(7):2989-98. PubMed ID: 26872791
[TBL] [Abstract][Full Text] [Related]
3. Adherence to guidelines for use of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia: results of a retrospective study of an electronic medical-records database in the United States, 2002-2006.
Luo W; Nordstrom BL; Fraeman K; Nordyke R; Ranganathan G; Linz HE; Winterkorn A; Stokes M; Ross SD; Knopf K
Clin Ther; 2008 Dec; 30(12):2423-35. PubMed ID: 19167601
[TBL] [Abstract][Full Text] [Related]
4. End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemia.
Hoque S; Chen BJ; Schoen MW; Carson KR; Keller J; Witherspoon BJ; Knopf KB; Yang YT; Schooley B; Nabhan C; Sartor O; Yarnold PR; Ray P; Bobolts L; Hrushesky WJ; Dickson M; Bennett CL
PLoS One; 2020; 15(6):e0234541. PubMed ID: 32584835
[TBL] [Abstract][Full Text] [Related]
5. Changes in the use of erythropoiesis-stimulating agents (ESAs) and red blood cell transfusion in patients with cancer amidst regulatory and reimbursement changes.
Gawade PL; Berlin JA; Henry DH; Tomita D; Brooks BD; Franklin J; Bradbury BD; Critchlow CW
Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1357-1366. PubMed ID: 28809079
[TBL] [Abstract][Full Text] [Related]
6. Erythropoiesis-stimulating agents (ESAs): do they still have a role in chemotherapy-induced anemia (CIA)?
Bormanis J; Quirt I; Chang J; Kouroukis CT; MacDonald D; Melosky B; Verma S; Couture F
Crit Rev Oncol Hematol; 2013 Aug; 87(2):132-9. PubMed ID: 23357249
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of cancer chemotherapy-associated anemia in Japan - conditions and issues].
Yoshino I
Gan To Kagaku Ryoho; 2014 Apr; 41(4):426-31. PubMed ID: 24743358
[TBL] [Abstract][Full Text] [Related]
8. Trends in Erythropoiesis-stimulating agent use and blood transfusions for chemotherapy-induced anemia throughout FDA's risk evaluation and mitigation strategy lifecycle.
Vega A; Zhang R; Wong HL; Wernecke M; Alexander M; Feng Y; Lo AC; Lufkin B; Ryan Q; Izem R; MaCurdy TE; Kelman JA; Graham DJ
Pharmacoepidemiol Drug Saf; 2021 May; 30(5):626-635. PubMed ID: 33534188
[TBL] [Abstract][Full Text] [Related]
9. Questionnaire-based survey on chemotherapy-induced anemia.
Tanaka A; Yoshino I; Makino S; Katsumata N; Takahashi K; Kuwano H; Maehara Y; Nishiyama M
Int J Clin Oncol; 2014; 19(3):411-20. PubMed ID: 24610155
[TBL] [Abstract][Full Text] [Related]
10. Anemia and erythropoiesis-stimulating agent administration in patients with non-Hodgkin lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisolone ± rituximab chemotherapy: results from an observational study.
Haioun C; Salar A; Pettengell R; Johnsen HE; Duehrsen U; Rossi FG; Verhoef G; Schwenkglenks M; Jaeger U; Hamilton L; Pujol B; Lugtenburg PJ
Leuk Lymphoma; 2011 May; 52(5):796-803. PubMed ID: 21338278
[TBL] [Abstract][Full Text] [Related]
11. Transfusions increase with nationally driven reimbursement changes of erythropoiesis stimulating agents for chemotherapy-induced anemia.
Yu JM; Shord SS; Cuellar S
J Oncol Pharm Pract; 2011 Dec; 17(4):360-5. PubMed ID: 20826550
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy-induced anemia and oncologist perception on treatment: results of a web-based survey.
Cortinovis D; Beretta G; Piazza E; Luchena G; Aglione S; Bertolini A; Buzzoni R; Cabiddu M; Carnaghi C; Danova M; Farina G; Ferrari V; Frascaroli M; Reni M; Tansini G;
Tumori; 2013; 99(1):45-50. PubMed ID: 23548999
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy-induced anemia: the story of darbepoetin alfa.
Vansteenkiste J; Wauters I; Elliott S; Glaspy J; Hedenus M
Curr Med Res Opin; 2013 Apr; 29(4):325-37. PubMed ID: 23323876
[TBL] [Abstract][Full Text] [Related]
14. Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy.
Wauters I; Vansteenkiste J
Expert Rev Anticancer Ther; 2012 Nov; 12(11):1383-90. PubMed ID: 23113603
[TBL] [Abstract][Full Text] [Related]
15. End of an era for erythropoiesis-stimulating agents in oncology.
Schoen MW; Hoque S; Witherspoon BJ; Schooley B; Sartor O; Yang YT; Yarnold PR; Knopf KB; Hrushesky WJM; Dickson M; Chen BJ; Nabhan C; Bennett CL
Int J Cancer; 2020 May; 146(10):2829-2835. PubMed ID: 32037527
[TBL] [Abstract][Full Text] [Related]
16. Impact of changes in reimbursement policies and institutional practice algorithm for utilization of erythropoietic-stimulating agents on treatment patterns and costs in anemic lymphoma patients.
Lal LS; Raju A; Miller LA; Chen H; Arbuckle R; Sansgiry SS
Support Care Cancer; 2010 Feb; 19(2):251-9. PubMed ID: 20101414
[TBL] [Abstract][Full Text] [Related]
17. Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron.
Henry DH; Dahl NV; Auerbach MA
Am J Hematol; 2012 Mar; 87(3):308-10. PubMed ID: 22262486
[TBL] [Abstract][Full Text] [Related]
18. Erythropoiesis-stimulating agents in cancer patients: reflections on safety.
Wauters I; Vansteenkiste J
Expert Rev Clin Pharmacol; 2011 Jul; 4(4):467-76. PubMed ID: 22114856
[TBL] [Abstract][Full Text] [Related]
19. The Impact of the Risk Evaluation Mitigation Strategy for Erythropoiesis-Stimulating Agents on Their Use and the Incidence of Stroke in Medicare Subjects with Chemotherapy-Induced Anemia with Lung and/or Breast Cancers.
Hollingsworth K; Romney MC; Crawford A; McAna J
Popul Health Manag; 2016 Feb; 19(1):63-9. PubMed ID: 26102512
[TBL] [Abstract][Full Text] [Related]
20. Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses.
Vansteenkiste J; Glaspy J; Henry D; Ludwig H; Pirker R; Tomita D; Collins H; Crawford J
Lung Cancer; 2012 Jun; 76(3):478-85. PubMed ID: 22277104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
